BPC-157 and Tirzepatide Together: What Is Known
BPC-157 and Tirzepatide taken together: what each one is, how each is regulated, and what is known about combining them.
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Interaction notes
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 3 results, 2 Oct 2026).
BPC-157 is not FDA approved, and we have no sourced data on combining it with Tirzepatide.
Each component
Side by side
Showing 14 of 14 fields where the two differ.
| Field | BPC-157 | Tirzepatide |
|---|---|---|
| Class | Gastric pentadecapeptide | GLP-1 / GIP dual agonist |
| Also called | BPC, body protection compound, Pentadecapeptide BPC 157 | tirz, tirze, Mounjaro, Zepbound |
| Category | Healing & recovery | GLP-1 & metabolic |
| FDA status | PCAC voted 8–6 for 503A (Jul 2026) | FDA approved (Mounjaro, Zepbound) |
| PCAC vote, Jul 2026 | PCAC voted 8–6 for the 503A list (Jul 2026); not finalized | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S0)BPC-157 is named in S0 (non-approved substances), prohibited at all times, in and out of competition. | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. |
| Anti-doping detection |
| None reportedanti-doping literature, as of 2 Oct 2026 |
| Half-life | less than 30 minIV and IM (single and repeated) (rat, beagle dog) · Frontiers in pharmacology 2022, PMID 36588717 | approximately 5 dayssubcutaneous · FDA label (Mounjaro) |
| Evidence strength | Human observational evidence, 3 of 4Strongest: Alternative therapies in health and medicine 2025, PMID 40131143 | Human RCT evidence, 4 of 4Strongest: Arthritis & rheumatology 2026, PMID 41903163 |
| Human studies we summarised | 3 human (0 randomized or controlled) of 24 summarised | 24 human (22 randomized or controlled) of 30 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 2 mg, 5 mg, 10 mg, 20 mg | 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 120 mg |
| US searches per month | 301,000 · Most searched | 1,220,000 · +30% searches |
| Named in FDA warning letters, 2026 | Not in the letters we track | Yes (24 Aug 2026; 31 Mar 2026) |
What people search
- bpc 157 and tirzepatide together40/mo
- bpc 157 and tirzepatide30/mo
- tirzepatide with bpc 15720/mo
- tirzepatide and bpc 157 together20/mo
- tirzepatide and bpc 15720/mo
- bpc 157 with tirzepatide20/mo
US monthly searches, Google Keyword Planner, Oct 2026. Shown so you can see which questions this page answers.
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
- 3FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
- 4Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 5World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 6Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS.Molecules (Basel, Switzerland) · 2023PMID 37959764Accessed 2 Oct 2026
- 7Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H.Drug testing and analysis · 2017PMID 28035768Accessed 2 Oct 2026
- 8Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.Frontiers in pharmacology · 2022PMID 36588717Accessed 2 Oct 2026
- 9Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.Alternative therapies in health and medicine · 2025PMID 40131143Accessed 2 Oct 2026
- 10Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.Alternative therapies in health and medicine · 2024PMID 39325560Accessed 2 Oct 2026
- 11Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.Joint diseases and related surgery · 2026PMID 42542926Accessed 2 Oct 2026
- 12These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 13Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
- 14Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
- 15Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
- 16PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 17Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026
- 18Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
Found an error? Report a correction.